Milestone Scientific Inc.

Good morning everyone and welcome to the Milestone Scientific's second quarter 2025 financial results and business update conference call. At this time all participants are in a listen only mode and the floor will be open for questions following the presentation. If anyone should require operator assistance during this conference please press star zero on your phone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, David Waldman of Crescendo Communications. David, the floor is yours.

Thank you, Jenny. Good morning, and thank you all for joining Milestone Scientific's second quarter 2025 financial results conference call. On the call with us today are Neil Goldman, Chairman, Eric Hines, Chief Executive Officer, and Keisha Harkam, Vice President of Finance at Milestone Scientific. The company issued a press release yesterday afternoon containing second quarter 2025 financial results, which is also posted on the company's website. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at 212-671-1020. Company's management will now provide prepared remarks reviewing the financial and operational results for the second quarter ended June 30th, 2025. Before we get started, we'd like to remind everyone that during this conference call, we may make forward-looking statements regarding timing and financial impact of Milestone's ability to implement its business plan, expected revenues, and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive, and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in milestones, periodic filings of the Securities and Exchange Commission, including without limitation milestones report on Form 10-K for the year ended December 31st, 2024, and milestones report on Form 10-Q for the second quarter ended June 30th, 2025. The forward-looking statements made during this call are based upon management's reasonable belief as of today's date, August 15th, Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. With that, we'll now turn the call over to Neil Goldman, Chairman of the Board. Please go ahead, Neil.

Thank you, David. Good morning, everyone, and welcome to Milestone's scientific second quarter 2025 conference call. Before we get into the results, I want to start with what I believe is one of the most important drivers of our future success, the recent additions to our leadership team. First, I'm pleased to introduce our newly appointed Chief Executive Officer, Eric Hines. Eric brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies and serving customers across multiple industries, including healthcare. He has built efficient, high-performance teams and delivered consistent topline growth. At Ex Libris, a division of Clarivate, Eric led operations across the U.S., Canada, and Latin America, substantially growing the business, ultimately generating over $100 million in revenue. Early in his career at Nice Systems, he managed a $90 million North American security business. Eric is a leader who knows how to execute at scale, and we're excited about the vision and energy he brings to Milestone. We also recently welcomed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Jason brings more than 30 years of experience in scaling commercial operations across healthcare and medical technology sectors. He's built national and international distribution network, driven strategic growth initiatives, and led successful ventures to acquisition. His expertise spans orthopedics, neurology, pain management, and digital imaging, making him a tremendous asset as we accelerate both our dental and medical businesses. On the governance side, Shantz Salingam has joined our board of directors. He brings in more than 20 years of global leadership in commercial scaling, reimbursement strategy, and product innovation across medical device and pharmaceutical industries. Shantz's experience and track record will be invaluable to Milestone as we look to expand adoption of our copy flow epidural and advance our commercial execution. I believe this new leadership team is built for acceleration with the talent, experience, and commitment to take Milestone to the next level. And with that, it is my pleasure to turn the call over to Eric.